<DOC>
	<DOCNO>NCT02051062</DOCNO>
	<brief_summary>The purpose study verify pediatric dose recommendation BAT® pediatric patient treat BAT® due confirm suspected case botulism . One 5 mL blood sample obtain within 24 hour post BAT® administration . Study BT-011 run concurrently BAT patient registry ( BT-010 ) .</brief_summary>
	<brief_title>BT-011 Pharmacokinetics Botulism Antitoxin Heptavalent Pediatric Patients</brief_title>
	<detailed_description>Objectives : The purpose study collect one serum sample pediatric patient order analyze pharmacokinetics BAT® verify currently approve pediatric dose recommendation . Protocol Design : This single arm , multi-site Pharmacokinetics study pediatric patient treat BAT® . The study begin participation study confirm physician inform consent/assent obtain patient and/or guardian . Concurrent participation BAT patient registry ( BT-010 ) treat physician/facility encourage collect safety clinical outcome data . Assessments : One 5 mL blood collect yield 2 mL serum sample collect post-BAT® administration . The blood sample collect later 24 hour post BAT® administration . To ensure sufficient detectable circulating level BAT® pharmacokinetic analysis target window time collection 6 24 hour post-BAT® administration . Pharmacokinetic Efficacy Parameters : The BAT® serum concentration ( ) obtain model use population pharmacokinetic approach base previously develop model BAT® healthy adult human subject toxin serotypes A-G . Individual Bayesian Pharmacokinetics parameter ( i.e . clearance ( CL ) , volume distribution ( Vc ) , volume distribution central peripheral compartment ( Vp ) ) correspond exposure metric derive population analysis . Primary Endpoints : The primary endpoint dosage level pharmacokinetic equivalence reach i.e . dosage BAT® effective symptom botulism . Following estimation exposure pediatric patient , similar do adult subject , margin efficacy 90 % survival estimate order verify appropriateness administer pediatric dose .</detailed_description>
	<mesh_term>Botulism</mesh_term>
	<mesh_term>Antitoxins</mesh_term>
	<mesh_term>Botulinum Antitoxin</mesh_term>
	<criteria>Informed consent/assent ( applicable ) require provision serum sample Cangene . Pediatric patient [ age category : pediatric—preterm term newborn infant ( 0 27 day ) , infants toddler ( 28 day 23 month ) , child ( 2 11years ) , adolescent ( 12 16years ) ] Confirmed suspect exposure botulinum toxin . Treatment BAT® deploy Strategic National Stockpile state stockpile . If blood sample collect pediatric subject within 24 hour BAT® administration subject exclude study . The 5 mL blood sample volume deem unsafe base patient weight .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>BAT</keyword>
	<keyword>Pediatric</keyword>
</DOC>